Literature DB >> 22935919

Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer cells treated with sexual hormones and flutamide.

Da Yue Tong1, Xin yao Wu, Hong yu Sun, Yi Jin, Zhuo wei Liu, Fang jian Zhou.   

Abstract

The study aims to investigate the changes and regulation of androgen receptor and insulin-like growth factor-1 in the PC3 prostate cells treated with 5α-dihydrotestosterone, estrone, and flutamide. The PC3 cells were cultured and treated with 5α-dihydrotestosterone, estrone, and flutamide. Immunocytochemistry and Western blot were used to detect the expression of androgen receptor and insulin-like growth factor-1. The androgen receptor expression was analyzed by Western blot and optic density scan in the presence or absence of various kinase inhibitors. The statistical calculations were performed with the statistics-analyzing software package SPSS 13.0. A P <0.05 was considered statistically significant. The concentrations of 5α-dihydrotestosterone and flutamide could almost not change the expression of androgen receptor and insulin-like growth factor-1 in PC3. But, the concentrations of estrone could increase the expression of androgen receptor and insulin-like growth factor-1 when PC3 cells are exposed to the studied concentration at various times. The expression of androgen receptor was regulated by the inhibitor of signal pathways of PI3, MEK1/2, and JUK. The expressions of androgen receptor and insulin-like growth factor-1 were influenced by estrone and were not influenced by 5α-dihydrotestosterone and flutamide in PC3 cells. And, the expression of androgen receptor was regulated by multiple signal pathways.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22935919     DOI: 10.1007/s13277-012-0475-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  15 in total

Review 1.  Mechanisms of the development of androgen independence in prostate cancer.

Authors:  Alan So; Martin Gleave; Antonio Hurtado-Col; Colleen Nelson
Journal:  World J Urol       Date:  2005-01-27       Impact factor: 4.226

Review 2.  Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer.

Authors:  Masaki Shiota; Akira Yokomizo; Naohiro Fujimoto; Seiji Naito
Journal:  Curr Cancer Drug Targets       Date:  2011-09       Impact factor: 3.428

3.  Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.

Authors:  Yong Wang; Chen Shao; Chang-Hong Shi; Lei Zhang; Hong-Hong Yue; Peng-Fei Wang; Bo Yang; Yun-Tao Zhang; Fan Liu; Wei-Jun Qin; He Wang; Guo-Xing Shao
Journal:  Asian J Androl       Date:  2005-12       Impact factor: 3.285

Review 4.  Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.

Authors:  Changmeng Cai; Steven P Balk
Journal:  Endocr Relat Cancer       Date:  2011-08-30       Impact factor: 5.678

5.  In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).

Authors:  T Nickerson; F Chang; D Lorimer; S P Smeekens; C L Sawyers; M Pollak
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

6.  Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.

Authors:  Kazuya Mikami; Kotaro Ozasa; Masahiro Nakao; Tsuneharu Miki; Kyohei Hayashi; Yoshiyuki Watanabe; Mitsuru Mori; Fumio Sakauchi; Masakazu Washio; Tatsuhiko Kubo; Koji Suzuki; Kenji Wakai; Kei Nakachi; Kazuo Tajima; Yoshinori Ito; Yutaka Inaba; Akiko Tamakoshi
Journal:  Asian Pac J Cancer Prev       Date:  2009-12

7.  Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.

Authors:  Da Yue Tong; Xing Qiao Wen; Yi Jin; Zhuo Wei Liu; Hong Yu Sun; Fang Jian Zhou; Xin Yao Wu
Journal:  Asian Pac J Cancer Prev       Date:  2010

Review 8.  Mechanisms mediating androgen receptor reactivation after castration.

Authors:  Xin Yuan; Steven P Balk
Journal:  Urol Oncol       Date:  2009 Jan-Feb       Impact factor: 3.498

9.  Modification of androgen receptor function by IGF-1 signaling implications in the mechanism of refractory prostate carcinoma.

Authors:  Toshihiko Yanase; Wuqiang Fan
Journal:  Vitam Horm       Date:  2009       Impact factor: 3.421

10.  Androgens, growth factors, and risk of prostate cancer: the Multiethnic Cohort.

Authors:  Jasmeet K Gill; Lynne R Wilkens; Michael N Pollak; Frank Z Stanczyk; Laurence N Kolonel
Journal:  Prostate       Date:  2010-06-01       Impact factor: 4.104

View more
  2 in total

1.  Insulin-like growth factor 1 myocardial expression decreases in chronic alcohol consumption.

Authors:  Francesc Borrisser-Pairó; Emilia Antúnez; Ester Tobías; Joaquim Fernández-Solà
Journal:  Regen Med Res       Date:  2013-10-01

2.  A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.

Authors:  Monica Archibald; Tara Pritchard; Hayley Nehoff; Rhonda J Rosengren; Khaled Greish; Sebastien Taurin
Journal:  Int J Nanomedicine       Date:  2016-01-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.